Expectations and Beliefs of Transgender People Regarding Hormonal Treatment

• Sponsor: Central Hospital, Nancy, France (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05474768
• Collaborator: (none)
• Enrollment: 20
• Location: 1
• Anticipated Duration (Months): 10.9
• Patients Per Site Per Month: 1.8

Study Details

Study Description

Brief Summary

Hormonal treatment of gender dysphoria can have repercussions on metabolism, cardiovascular system and fertility and represents à potential oncological risk. According to the recommendations of the Endocrine society. Therefore, initial assessment and follow-up visits are necessary and must be carried out to avoid the apparition of potentially undesirable effects.

Condition or Disease	Intervention/Treatment	Phase
Transgenderism	Other: no intervention

Study Design

• Study Type: Observational
• Anticipated Enrollment: 20 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Expectations and Beliefs of Transgender People Regarding Hormonal Treatment
• Actual Study Start Date: Feb 2, 2022
• Anticipated Primary Completion Date: Nov 1, 2022
• Anticipated Study Completion Date: Jan 1, 2023

Outcome Measures

Primary Outcome Measures

1. Describe expectations and beliefs of transgener people about hormonal therapy [12 months]

   qualitative analysis of qualitative data from collective discussions (focus groups)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 80 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• being a parent of adolescent/child presenting Gender dysphoria

• adult subject (age > 18 years) presenting Gender dysphoria

non-inclusion criteria

• Severe, uncontrolled psychiatric or somatic illness

• Chronic alcoholism

• Substance abuse

• Refusal or linguistic, physical or psychological incapacity to participate in the study

• Ongoing pregnancy

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	CHRU de Nancy	Nancy		France

Sponsors and Collaborators

• Central Hospital, Nancy, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: EVA FEIGERLOVA, Principal investigator, Central Hospital, Nancy, France
• ClinicalTrials.gov Identifier: NCT05474768
• Other Study ID Numbers: 2021PI221
• First Posted: Jul 26, 2022
• Last Update Posted: Jul 26, 2022
• Last Verified: Jul 1, 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Jul 26, 2022